<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729582</url>
  </required_header>
  <id_info>
    <org_study_id>MUST</org_study_id>
    <nct_id>NCT04729582</nct_id>
  </id_info>
  <brief_title>Autologous Muscle Stem Cell Therapy for Treatment of Congenital Urinary Incontinence in Epispadias Patients</brief_title>
  <acronym>MUST</acronym>
  <official_title>Combined Phase 1 and 1/2a Clinical Trial Evaluating the Safety and Efficacy of an Autologous Muscle Stem Cell Therapy in the Treatment of Urinary Incontinence in Isolated Epispadias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simone Spuler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the safety and efficacy of an autologous muscle stem&#xD;
      cell therapy in the treatment of congenital urinary incontinence in isolated epispadias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epispadias is the mildest form of exstrophy-epispadias complex (EEC); a congenital&#xD;
      malformation disorder involving the midline abdominal and genitourinary structures. Patients&#xD;
      with epispadias have a defect in the urethral sphincter resulting in urinary incontinence.&#xD;
      This trial investigates the injection of autologous primary human muscle stem cells into the&#xD;
      urethral sphincter with the aim of repairing the defect and restore the anatomic ability for&#xD;
      continence.&#xD;
&#xD;
      Eligible participants will undergo muscle biopsy during a routine cystoscopy. Acquired muscle&#xD;
      tissue is used for the isolation and expansion of muscle stem cells ex-vivo. Muscle stem&#xD;
      cells are injected into the urethral sphincter under visual control using cystoscopy.&#xD;
      Participants are assessed for safety and efficacy for a minimum of 12 months&#xD;
      post-intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2022</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Intervention-related Adverse Events</measure>
    <time_frame>Upto 12 months post-intervention</time_frame>
    <description>Characterization of type, incidence, severity, and duration of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Leak Point Pressure (LPP)</measure>
    <time_frame>Six months post-intervention</time_frame>
    <description>Change in LPP is calculated from baseline measurement</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Epispadias, Male</condition>
  <arm_group>
    <arm_group_label>Verum Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive primary human muscle stem cells as one-time injection into the urethral sphincter region under visual control using cystoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo solution as one-time injection into the external urethral sphincter region under visual control using cystoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Primary human muscle stem cells (Satori-01)</intervention_name>
    <description>Primary human muscle stem cells are isolated from patient's muscle tissue and expanded ex-vivo. They are injected into the urethral sphincter region as a one-time autologous treatment.</description>
    <arm_group_label>Verum Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is the injection solution without muscle stem cells.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Isolated epispadias&#xD;
&#xD;
          -  Aged ≥ 3 years&#xD;
&#xD;
          -  Urinary incontinence as defined according to the International Children´s Continence&#xD;
             Society&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute or chronic inflammatory local or systemic disease&#xD;
&#xD;
          -  Coagulation Disorder&#xD;
&#xD;
          -  Previous adverse reaction to anesthesia&#xD;
&#xD;
          -  Congenital heart defect, cardiac arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne K Ebert, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Urology, Department for Urology University of Ulm, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Spuler, Prof. Dr.</last_name>
    <phone>+49 (0) 30 450 540 501</phone>
    <email>simone.spuler@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinic for Pediatric Urology in cooperation with University Hospital Regensburg, St. Hedwig Hospital</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Wolfgang H Rösch, Prof. Dr.</last_name>
      <phone>+49 (0) 941 369 5453</phone>
      <email>wolfgang.roesch@barmherzige-regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang H Rösch, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Urology, Department for Urology University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne K Ebert, Prof. Dr.</last_name>
      <phone>+49 (0) 731 500 58000</phone>
      <email>Anne-Karoline.Ebert@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Anne K Ebert, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Simone Spuler</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Isolated epispadias</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Muscle stem cell therapy</keyword>
  <keyword>Autologous cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Epispadias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

